Articles on Approaches for Accelerating Product Development



     •     Financing and Coordination of Health Research: Perspectives from Nonprofits on Accelerating Product Development and Improving Access for Low- and Middle-Income Countries. Global Health Technologies Coalition. Briefing Paper, Volume 1. May 2013.

     •     Briefing Paper: Volume 2: Financing Perspectives from nonprofits on accelerating product development and improving access for low- and middle-income countries. GHTC.  September 2013.

     •     Briefing Paper, Volume 3: Improving the affordability, availability, and acceptability of health technologies. GHTC. December 2013

     •     Strengthening Mechanisms to Prioritize, Coordinate, Finance, and Execute R&D to Meet Health Needs in Developing Countries. IOM Discussion Paper. January 2013

     •     Public-private partnerships for global health:  How PATH advances technologies through cross-sector collaboration. PATH. March 2013.

     •     Developing multipurpose reproductive health technologies: An integrated strategy. Harrison P et al. AIDS Research and Treatment. 1 March 2013

     •     The story of artesunate--mefloquine (ASMQ), innovative partnerships in drug development: case study. Wells S et al. Malaria Journal 2013, 12:68 doi 10.1186/1475-2875-12-68 Published: 21 February 2013

     •     Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory? Rottingen J-A et al. The Lancet, Volume 382, Issue 9900, Pages 1286 - 1307, 12 October 2013

     •     MMV in partnership: the Eurartesim® experience. Ubben D & Poll EM. Malaria Journal 2013, 12:211 doi 10.1186/1475-2875-12-211

     •     A database on global health research in Africa.  Collins F et al. The Lancet Global Health, Early Online Publication, 5 July 2013

     •     An Innovative Approach to R&D for Neglected Patients: Ten Years of Experience and Lessons Learned by DNDi.  DNDi.  December 2013.

     •     PLOS and DNDi: A Decade of Open Access and NTD R&D. PLOS Medicine Collection, December 2013


     •     Developing New Drugs & Vaccines for Neglected Diseases of the Poor: The Product Developer Landscape.  BVGH. March 2012.

     •     Competing by Saving Lives: How Pharmaceutical and Medical Device Companies Create Shared Value in Global Health.  FSG Report. March 2012.

     •     Global Report for Research on Infectious Diseases of Poverty. TDR/WHO. April 2012

     •     Key recommendations from product development partnerships (PDPs) for inclusion in Horizon 2020. April 2012. PDP_Position_Paper_HORIZON 2020 April 2012.pdf

     •     Saving Lives and Creating Impact: Why investing in global health research works.  GHTC & Policy Cures. April 2012.

     •     Creating the tools for tomorrow: Investing in global health R&D.  Global Health Technologies Coalition, Bill & Melinda Gates Foundation, Policy Cures, and DSW. May 2012

     •     India’s Role in Global Health R&D. Wilson P & Rao A. Results for Development. August 2012.

     •     Technologies for Global Health. The Imperial College London/ Lancet Commission. August 2012.

     •     Seizing the Reins: From translational science to manufacturing, PDPs have significantly expanded their mandates and built labs that they believe fill an important niche in global health research Regina McEnery. IAVI Report. Vol 16, No.4. Nov-Dec 2012.

     •     The Global Health Social Enterprise: An Emerging Approach to Global Health R&D.  Andrew Roberston.  Centrer for Global Health R&D Policy Assessment.  Results for Development Institute. December 2012.

     •     Saving Lives and Creating Impact:  EU investment in poverty -related neglected diseases.  DSW & Policy Cures.  Published Sept 26 2012.

     •     PATH launches new product development slideshow. July 2012

     •     Technologies for global health. Howitt P et al. The Lancet, Volume 380, Issue 9840, Pages 507 - 535, 4 August 2012

     •     Developing Drugs for Neglected Diseases: PATH Advances High-Quality, Affordable Treatments for the Developing World. PATH. September 2012

     •     Ingredients of a Successful Public-Private Partnership: A Case Study of the Landmark Vaccine Vial Monitor Partnership. PATH. September 2012.

     •     Neglected Diseases and Drug Discovery. An edited volume published by the Royal Society of Chemistry, co-edited by MMV’s CSO, Tim Wells. January 2012.


     •     Opportunities, Challenges and Good Practices in International Research Cooperation between Developed and Developing Countries. OECD. April 2011. http://www.oecd.org/dataoecd/40/16/47737209.pdf

     •     Public Private Partnerships (PPPs) in Advancing Global Health - A Development Approach for Germany?  Conference Report.  June 2011. Conference Report International Conference on PPPs in Global Health.pdf

     •     The Profits of Nonprofit: The surprising results when drug development and altruism collide.  Scudellari M. The Scientist. Volume 25, Issue 1. Page 54.

     •     New Strategies For Innovation In Global Health: A Pharmaceutical Industry Perspective.  A Witty.  Health Affairs. January 2011 vol. 30 no. 1 118-126

     •     The role of public-sector research in the discovery of drugs and vaccines. Stevens AJ et al. New England Journal of Medicine. 9 February 2011

     •     First public-private vaccine. Subbaraman N. Nature Biotechnology. 7 February 2011; 29:99.

     •     Traditional drug-discovery model ripe for reform. Cressey D.  Nature 471, 17-18 (2011). Published online 2 March 2011

     •     Demythologizing the high costs of pharmaceutical research. Light DW & Warburton R. BioSocieties advance online publication 7 February 2011; doi: 10.1057/biosoc.2010.40 

     •     Gaps in Research.  Eiss R & Glass R.  Global Health. Winter 2011.

     •     Overcoming gaps to advance global health equity: a symposium on new directions for research.  Frenk J & Chen L. Health Research Policy and Systems 2011, 9:11

     •     Global Health Primer 2011.  BIO Ventures for Global Health. March 2011.

     •     Technology Transfer: A collaborative Approach to Improve Global Health. The Research Based Pharmaceutical Experience.  IFPMA. March 2011.

     •     Global health philanthropy and institutional relationships: how should conflicts of interest be addressed? Stuckler D et al. PLoS Medicine. 11 April 2011; 8(4)

     •     Health Technologies and Innovation in the Global Health Arena.  Sinha SR & Barry M.  N Engl J Med 2011; 365:779-782 September 1, 2011

     •     GHTC 2011 Policy Report: Sparking Innovation to Save Lives: How the US can advance global health through new technologies.

     •     Product Development Partnerships: Case studies of a new mechanism for health technology innovation. Mahoney RT. Health Research Policy and Systems 2011, 9:33

     •     The Power of Product Development Partnerships.  Looney W. Pharmaceutical Executive.  Sept  2011.  Vol. 31. No. 9.

     •     Future Medicinal Chemistry -  two issues focusing on Neglected Diseases.  Includes:

•     Drugs for neglected diseases: part 1.  Kaneko T. Future Medicinal Chemistry, August 2011, Vol. 3, No. 10, Pages 1235-1237.

•      Drugs for neglected diseases: part 2. Kaneko T. Future Medicinal Chemistry, September 2011, Vol. 3, No. 11, Pages 1329-1330.

•     Research Spotlight: The TB Alliance: overcoming challenges to chart the future course of TB drug development. Ginsberg A. Future Medicinal Chemistry, August 2011, Vol. 3, No. 10, Pages 1247-1252.

•     Drugs for Neglected Diseases initiative model of drug development for neglected diseases: current status and future challenges. Chang S and Ioset J-R. Future Medicinal Chemistry, September 2011, Vol. 3, No. 11, Pages 1361-1371.

•     Challenges in antimalarial drug discovery. Burrows JN et al. Future Medicinal Chemistry, September 2011, Vol. 3, No. 11, Pages 1401-1412.

•     The importance of patent sharing in neglected disease drug discovery.  Edlin C. Future Medicinal Chemistry. September 2011, Vol. 3, No. 11, Pages 1331-1334 , DOI 10.4155/fmc.11.101


     •     Drug development for neglected diseases: pharma's influence.  The Lancet (Editorial).  375(9708).  January 2 2010.

     •     A flexible blueprint for the future of drug development.  R Barker.  The Lancet (Comment). 375 (9712).  January 30.

     •     University leadership for innovation in global health and HIV/AIDS diagnostics. Palamountain KM and Stewart KA. Global Public Health: An International Journal for Research, Policy and Practice. 29 January 2010:1744-1706.

     •     Pretoria Expert meeting - Pharmaceutical Innovation in Africa.  February 2010

COHRED-NEPAD study on pharmaceutical innovation in Africa

Final statement from the meeting

     •     The role of Product Development Partnerships in research and development for neglected diseases.  Moran M et al. International Health Journal.  2(2): 114-122. June 2010.

     •     University leadership for innovation in global health and HIV/AIDS diagnostics. Palamountain KM and Stewart KA. Global Public Health: An International Journal for Research, Policy and Practice. 29 January 2010:1744-1706.

     •     Developing ANDI: A Novel Approach to Health Product R&D in Africa. Nwaka S et al. PLoS Med 7(6): e1000293. doi:10.1371/journal.pmed.1000293

     •     The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics.  Luzzatto L.  The Lancet, Volume 376, Issue 9742, Pages 739 - 741, 28 August 2010

     •     Innovative Product Development Partnerships for Global Health. IAVI Policy Brief. September 2010.

     •     "The best or the worst" end up in product development partnerships. Kondro W. Canadian Medical Association Journal. 14 October 2010

     •     Vaccine innovation done differently. Widdus R. Bulletin of the World Health Organization 2010;88:880-880

     •     Leveraging biotech's drug discovery expertise for neglected diseases. Joanna E Lowell & Christopher D Earl.  Nature Biotechnology. 27, 323 - 329 (2009).

     •     The African Network for Drugs and Diagnostics Innovation.  Tom Mobya-Okeyo,Robert G Ridley, Solomon Nwakda.  Lancet 2009; 373: 1507-1508.

     •     Case Studies for Global Health.  Alliance for Case Studies for Global Health.  2009.  

Discovery/Development Articles

     •     Breaking Down the Barriers to Sharing Knowledge

     •     HIV Vaccine Trial Centers Forge Research Network in Developing Countries

     •     Making New Medical Innovations Available in Developing Countries First, Where They're Needed Most

     •     Product Development Partnership Aims to Develop First Vaccine Against Malaria Parasite

     •     Historic Confluence Promotes Malaria Breakthroughs

     •     TB Alliance Partnership Charts Course for Future Neglected Disease Treatments

     •     Dengue Fever Partnership Changes the Rules for Vaccine Development

     •     Global Access License Between University and Biotech Benefits Developed and Developing World

     •     New Broad-Spectrum Vaccine Protects Against Most Pneumococcal Disease

     •     A Glaucoma Treatment Option With Global Promise

     •     The Africa Biofortified Sorghum Project Consortium: Food Safety and Fighting Malnutrition in Africa

     •     Public-Private Partnerships and Scientific Imperialism. TJ Tucker & MW Makgoba.  Science. 23 May 2008. Vol. 320. no. 5879, pp. 1016 – 1017

     •     Partnerships to Build Healthier Societies in the Developing World 2008.  IFPMA.  April 2008.

     •     Critical Review of the IFPMA Health Partnerships Survey 2007. LSE Health, London School of Economics & Political Science.  May 2008.

     •     Global Forum Update on Research for Health Volume 5: Fostering innovation for global health. 2008.

     •     The International AIDS Vaccine Initiative (IAVI) in a changing landscape of vaccine development: a public–private partnership as knowledge broker and integrator. J Chataway et al. European Journal of Development Research, 2007, 19(1):100–117

     •     The International AIDS Vaccine Initiative (IAVI): Is It Getting New Science and Technology to the World’s Neglected Majority? JC Chataway & J Smith. World Development, 2006, 34(1):16–30

     •     Developing Drugs For Developing Countries.  2006.  DB Ridley et al. Health Affairs.  25: 313-324

     •     Global Forum Updates on Research for Health

     •     Volume 6:  Innovating for the Health of All.  2009

     •     Volume 5:  Fostering innovation for Global Health. 2008

     •     Volume 4:  Equitable Access: research challenges for health in developing countries. 2007

     •     Volume 3:  Combating Disease and Promoting Health. 2006.

     •     Volume 2:   Poverty, Equity and Health Research.  2005

     •     Volume 1: Health research to achieve the Millennium Development Goals. 2005


     •     Public-Private Partnerships for Product Development: Financial, scientific and managerial issues as challenges to future success. Research Report For The World Health Organization Commission on Intellectual Property Rights, Innovation and Public Health.  Report by E Ziemba.  March 2005.

     •     A breakthrough in R&D for neglected diseases: new ways to get the drugs we need. M Moran.  PLoS Medicine, 2005.

     •     The new landscape of neglected disease drug development. Pharmaceutical Policy R&D Project.  London School of Economics. 2005.  

     •     Public–private partnership: an overview.  R Widdus. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99(Suppl. 1):S1–S8.  

     •     Public–private partnership: from there to here. SL Croft.  Transactions of the Royal Society of Tropical Medicine and Hygiene, 2005, 99 (Suppl. 1):S9-S14.

     •     Governing public–private infectious disease partnerships. K Buse. Brown Journal of World Affairs, 2004, 2:225–42.

     •     Public–private partnerships in health – a call to action. S Nishtar. Health Research Policy and Systems. 2004, 28, 2(1):5.

     •     Combating Diseases Associated with Poverty: Financing Strategies for Product Development and the Potential Role of Public-Private Partnerships.  IPPPH. Report by R Widdus and K White.  2004.

     •     Valuing Industry Contributions to Public-Private Partnerships for Health Product Development.  IPPPH. Report by H. Kettler & K. White. 2003.

     •     Editorial: Public–Private Partnerships Require Thoughtful Evaluation. R Widdus. Bulletin of the World Health Organization, 2003, 81(4):235.

     •     Initial Lessons from public–private partnerships in drug and vaccine development. C Wheeler & S Berkley. Bulletin of the World Health Organization, 2001, 79(8):728–734.

     •     A role for public–private partnerships in controlling neglected diseases? R. Ridley. Bulletin of the World Health Organization, 2001, 79(8) 771–777.

     •     Public –private health partnerships: a strategy for WHO.  K Buse & A Waxman. Bulletin of the World Health Organization, 2001, 79(8)748–754.

     •     Public–private partnerships. CHM Working Paper Series, 2001. Paper No. WG2:21. H Kettler & A Towse.

     •     Global public–private partnerships: part 1 – a new development in health? K Buse & G Walt. Bulletin of the World Health Organization, 2000, 78(4):549–561.

     •     Global public–private partnerships: part II – what are the health issues for global governance? K Buse & G Walt. Bulletin of the World Health Organization, 2000, 78(5):700.

     •     Public–private partnerships for public health. M Reich. Nature Medicine, June 2000, 6(6):617–620.